2027 ICD-10-CM Diagnosis Code T45.1X6AUnderdosing of antineoplastic and immunosuppressive drugs, initial encounter

ICD-10-CM Codes›S00–T88›T36-T50›T45

ICD-10-CM T45.1X6A
CMSSource: CMS FY 2027 ICD-10-CM dataset · Effective Oct 1, 2026 – Sep 30, 2027

T45.1X6A is a billable ICD-10-CM diagnosis code for underdosing of antineoplastic and immunosuppressive drugs, initial encounter. The 7th character A marks it as an initial encounter code, used while the patient is receiving active treatment. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 951. The code is not accepted as a principal diagnosis by the Medicare Code Editor. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Underdosing of drugs and medicaments, initial encounter.

Code Identity

ICD-10-CM Code
T45.1X6A
Billable Status
Yes — Valid for Submission
Code Describes
Underdosing of antineoplastic and immunosuppressive drugs, initial encounter
Short Description
Underdosing of antineoplastic and immunosup drugs, init
Parent Code
Underdosing of antineoplastic and immunosuppressive drugs

Code Classification

ChapterS00–T88Injury, poisoning and certain other consequences of external causes
SectionT36-T50Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances
CategoryT45Poisoning by, adverse effect of and underdosing of primarily systemic and hematological agents, not elsewhere classified
This CodeT45.1X6AUnderdosing of antineoplastic and immunosuppressive drugs, initial encounter

Code EditsBilling

Medicare Code Editor checks that affect claim validity for T45.1X6A.

There are selected codes that describe a circumstance which influences an individual's health status but not a current illness or injury, or codes that are not specific manifestations but may be due to an underlying cause. These codes are considered unacceptable as a principal diagnosis.

Coding GuidelinesGuidance

Underdosing refers to taking less of a medication than is prescribed by a provider or a manufacturer's instruction. Codes for underdosing should never be assigned as principal or first-listed codes. If a patient has a relapse or exacerbation of the medical condition for which the drug is prescribed because of the reduction in dose, then the medical condition itself should be coded.

The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of primarily systemic and hematological agents, not elsewhere classified (T45). Use the following options for the applicable episode of care:

  • A - initial encounter
  • D - subsequent encounter
  • S - sequela

Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2027, published by CMS and the National Center for Health Statistics.

Instructional NotesGuidance

Instructions from the official ICD-10-CM Tabular List that apply to T45.1X6A: its own notes plus those printed at T45.1, T45, block T36-T50, and Chapter 19. A note printed at a category, block or chapter applies to every code under it.

Includes

Further defines, or gives examples of, the content of the category.

From Block T36-T50 Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances applies to 3,186 codes
  • adverse effect of correct substance properly administered
  • poisoning by overdose of substance
  • poisoning by wrong substance given or taken in error
  • underdosing by (inadvertently) (deliberately) taking less substance than prescribed or instructed

Excludes1

Not coded here: the excluded code is never reported together with this one, unless the two conditions are unrelated.

From T45.1 Poisoning by, adverse effect of and underdosing of antineoplastic and immunosuppressive drugs applies to 18 codes
  • poisoning by, adverse effect of and underdosing of immune checkpoint inhibitors and immunostimulant drugs (T45.A)
  • poisoning by, adverse effect of and underdosing of tamoxifen (T38.6)
From Block T36-T50 Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances applies to 3,186 codes
  • toxic reaction to local anesthesia in pregnancy (O29.3-)

Excludes2

Not included here: the excluded condition is not part of this code, but a patient may have both, so both codes may be reported.

From Block T36-T50 Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances applies to 3,186 codes
  • abuse and dependence of psychoactive substances (F10-F19)
  • abuse of non-dependence-producing substances (F55.-)
  • immunodeficiency due to drugs (D84.821)
  • drug reaction and poisoning affecting newborn (P00-P96)
  • pathological drug intoxication (inebriation) (F10-F19)
From Chapter 19 (S00-T88) Injury, poisoning and certain other consequences of external causes applies to 41,187 codes

Code First

The underlying condition named in the note is sequenced before this code.

From Block T36-T50 Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances applies to 3,186 codes
  • for adverse effects, the nature of the adverse effect, such as:
  • adverse effect NOS (T88.7)
  • aspirin gastritis (K29.-)
  • blood disorders (D56-D76)
  • contact dermatitis (L23-L25)
  • dermatitis due to substances taken internally (L27.-)
  • nephropathy (N14.0-N14.2)

Use Additional Code

Add a second code, after this one, to fully describe the condition.

From Block T36-T50 Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances applies to 3,186 codes
  • code(s) to specify:
  • manifestations of poisoning
  • underdosing or failure in dosage during medical and surgical care (Y63.6, Y63.8-Y63.9)
  • underdosing of medication regimen (Z91.12-, Z91.13-)
From Chapter 19 (S00-T88) Injury, poisoning and certain other consequences of external causes applies to 41,187 codes
  • code to identify any retained foreign body, if applicable (Z18.-)

Notes

General instructions on how these codes are used.

From Block T36-T50 Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances applies to 3,186 codes
  • The drug giving rise to the adverse effect should be identified by use of codes from categories T36-T50 with fifth or sixth character 5.
From Chapter 19 (S00-T88) Injury, poisoning and certain other consequences of external causes applies to 41,187 codes
  • Use secondary code(s) from Chapter 20, External causes of morbidity, to indicate cause of injury. Codes within the T section that include the external cause do not require an additional external cause code
  • The chapter uses the S-section for coding different types of injuries related to single body regions and the T-section to cover injuries to unspecified body regions as well as poisoning and certain other consequences of external causes.

7th Character

Every code in the category takes a 7th character from the listed values, with the placeholder X filling any empty positions before it.

From T45 Poisoning by, adverse effect of and underdosing of primarily systemic and hematological agents, not elsewhere classified applies to 270 codes
  • The appropriate 7th character is to be added to each code from category T45
  • Ainitial encounter this code
  • Dsubsequent encounter
  • Ssequela

Source: CMS ICD-10-CM Tabular List. How to read instructional notes.

Referenced in Other NotesGuidance

Instructional notes printed at other codes that name T45.1X6A, its category, or a range that includes it.

Excludes1 3

These codes carry an Excludes1 note naming T45.1X6A: they are not reported together with it, unless the two conditions are unrelated.

  • T36 Poisoning by, adverse effect of and underdosing of systemic antibiotics
    antineoplastic antibiotics (T45.1-) names T45.1-, which includes this code
  • T37.5 Poisoning by, adverse effect of and underdosing of antiviral drugs
    cytarabine (T45.1-) names T45.1-, which includes this code
  • T45.A Poisoning by, adverse effect of and underdosing of immune checkpoint inhibitors and immunostimulant drugs
    poisoning by, adverse effect of and underdosing of antineoplastic and immunosuppressive drug (T45.1) names T45.1, which includes this code

Code Also 3

These codes say T45.1X6A may also be needed to fully describe the condition. The note gives no sequencing direction.

  • J34.81 Nasal mucositis (ulcerative)
    antineoplastic and immunosuppressive drugs (T45.1X-) names T45.1X-, which includes this code
  • K92.81 Gastrointestinal mucositis (ulcerative)
    antineoplastic and immunosuppressive drugs (T45.1X-) names T45.1X-, which includes this code
  • N76.81 Mucositis (ulcerative) of vagina and vulva
    antineoplastic and immunosuppressive drugs (T45.1X-) names T45.1X-, which includes this code

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR INJ029
Underdosing of drugs and medicaments, initial encounter
Default principal diagnosis: inpatient No · outpatient No

Table of Drugs and ChemicalsClinical

Substances in the Table of Drugs and Chemicals that reference this code family. Always confirm in the Tabular List before coding.

SubstanceAccidentalSelf-harmAssaultUndeter­minedAdverse
Effect
Under­dosing
AclarubicinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Actinomycin CT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Actinomycin DT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AdriamycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Alkylating drug NECT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Alkylating drug NEC::antimyeloproliferativeT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Alkylating drug NEC::lymphaticT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AltretamineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AmethopterinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AminoglutethimideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Aminopterin sodiumT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AmsacrineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Antagonist::folic acidT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Antagonist::pyrimidineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AnthramycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Antibiotic NEC::anticancerT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Antibiotic NEC::antineoplasticT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Anticancer agents NECT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AntimetaboliteT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Antimitotic agentT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Antineoplastic NECT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Antineoplastic NEC::alkaloidalT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Antineoplastic NEC::antibioticsT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Antineoplastic NEC::combinationT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Ara-CT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AsparaginaseT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AzacitidineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AzaribineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AzaserineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AzatepaT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AzathioprineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
BCNUT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
BenzcarbimineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
BleomycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
BroxuridineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Busulfan, busulphanT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
CactinomycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Cancer chemotherapy drug regimenT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
CarboplatinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
CarboquoneT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
CarmofurT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
CarmustineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
ChlorambucilT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
ChlorhexamideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
ChlormethineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
ChloropurineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Chromic::phosphate 32PT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Chromomycin A3T45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
CiclosporinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
CisplatinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
ColaspaseT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Corynebacterium parvumT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
CycloleucinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
CyclophosphamideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
CyclosporinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
CytarabineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Cytosine arabinosideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
CytoxanT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
DacarbazineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
DactinomycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
DaunomycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
DaunorubicinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
DemecolcineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
2-Deoxy-5-fluorouridineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
5-Deoxy-5-fluorouridineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
DibromodulcitolT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
DibromomannitolT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
DoxifluridineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
DoxorubicinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
DTICT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Elliptinium acetateT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
EnocitabineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
EpirubicinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
EstramustineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Ethyl::carbamateT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
EtoglucidT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
EtoposideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
FAC (fluorouracil + doxorubicin + cyclophosphamide)T45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
FloxuridineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
FluorodeoxyuridineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
FluorouracilT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Folic acid::antagonistT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
FtorafurT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Gold::colloidal (l98Au)T45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
GoserelinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
HexamethylmelamineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Hormone::cancer therapyT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
HydroxycarbamideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
HydroxyureaT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
IdarubicinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
IfosfamideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Imidazole-4-carboxamideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Immunosuppressive drugT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
InproquoneT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
IproplatinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
IsophosphamideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
LeukeranT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
LomustineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
LonidamineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
M-AMSAT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MannomustineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MatulaneT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MechlorethamineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MelphalanT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MercaptopurineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MethotrexateT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Methyl::CCNUT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MetoprineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MithramycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MitobronitolT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MitoguazoneT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MitolactolT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MitomycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MitopodozideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MitotaneT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MitoxantroneT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MopidamolT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MOPP (mechlorethamine + vincristine + prednisone + procarbazine)T45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Muromonab-CD3T45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Mustard (emetic)::nitrogenT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MustineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
M-vacT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MyelobromalT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MyleranT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
NimustineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Nitrogen::mustardT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
OlivomycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
OncovinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
ParoxypropioneT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
PentostatinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
PeplomycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Phenyl::hydrazine::antineoplasticT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Phenylalanine mustardT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
PipobromanT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
PirarubicinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
PlicamycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
PorfiromycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
PrednimustineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
ProcarbazineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
PteroyltriglutamateT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Purine analogue (antineoplastic)T45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
PurinetholT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Pyrimidine antagonistT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
RazoxaneT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
RubidomycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
RufocromomycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
SarcolysinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
SarkomycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
SemustineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Sodium::aminopterinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
StreptozocinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
StreptozotocinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TauromustineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TegafurT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TEMT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TeniposideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TEPAT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
ThalidomideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
ThioguanineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
ThiotepaT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TioguanineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TreosulfanT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TretamineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TriaziquoneT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TrichlormethineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TrichlorotriethylamineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TriethanomelamineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TriethylenemelamineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TriethylenephosphoramideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TriethylenethiophosphoramideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TrimetrexateT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TrimustineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TrofosfamideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Uracil mustardT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
UramustineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
UrethaneT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
VinblastineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
VincamineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
VincristineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
VindesineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Vinorelbine tartrateT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
ZinostatinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
ZorubicinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6

Patient EducationClinical

Medication Errors

Medicines treat infectious diseases, prevent problems from chronic diseases, and ease pain. But medicines can also cause harmful reactions if not used correctly. Errors can happen in the hospital, at the health care provider's office, at the pharmacy, or at home. You can help prevent errors by:

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert T45.1X6A to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
No Map There is no ICD-9 equivalent for this code.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2026No changes
FY 2027CurrentCurrent code set, no changesEffective October 1, 2026 through September 30, 2027.

Questions About T45.1X6AOverview

Is T45.1X6A (Underdosing of antineoplastic and immunosuppressive drugs) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report underdosing of antineoplastic and immunosuppressive drugs, initial encounter on HIPAA-covered claims from October 1, 2026 through September 30, 2027.

What does the 7th character A in T45.1X6A mean?

The final character A marks the initial encounter: use it while the patient is receiving active treatment for underdosing of antineoplastic and immunosuppressive drugs, such as an emergency visit or first evaluation.

What MS-DRG does T45.1X6A group to?

On inpatient claims, underdosing of antineoplastic and immunosuppressive drugs, initial encounter maps to MS-DRG 951 (other Factors Influencing Health Status), which carries a relative weight of 0.5574. Higher weights mean higher Medicare reimbursement.

Can T45.1X6A be a principal diagnosis?

No. The Medicare Code Editor rejects this code as a principal diagnosis because underdosing of antineoplastic and immunosuppressive drugs, initial encounter describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.

Can T45.1X6A be reported with T45.A?

Not as a rule. The Excludes1 note at T45.1, which applies to T45.1X6A, lists "poisoning by, adverse effect of and underdosing of immune checkpoint inhibitors and immunostimulant drugs (T45.A)". An Excludes1 note means the excluded code is never reported together with this one; the only exception is when the two conditions are unrelated to each other (Official Guidelines, Section I.A.12.a).